Showing results (191-200 of 523) with videos related to
Sort By:
Pageof 53
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 2015
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patientsFayçal Djenidi, Julien Adam, Aïcha Goubar, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2020
Can radiation-recall predict long lasting response to immune checkpoint inhibitors?Eric Deutsch, Benjamin Besse, Jérôme Le Pavec, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancerJean-Charles Soria, Egbert Smit, David Khayat, et al.Frontiers in Immunology|February 1, 2024
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarkerKarim Amrane, Coline Le Meur, Benjamin Besse, et al.The Lancet. Oncology|July 3, 2026
Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trialLeonardo Brunetti, Valentina Santo, David J Pinato, et al.European Journal of Cancer (Oxford, England : 1990)|November 11, 2022
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysisGiuseppe Viscardi, Antonino C Tralongo, Francesco Massari, et al.Journal of Thoracic Disease|June 29, 2018
Do immune checkpoint inhibitors need new studies methodology?Roberto Ferrara, Sara Pilotto, Mario Caccese, et al.Journal of Personalized Medicine|June 2, 2021
Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal CancerJose Carlos Benitez, Marc Campayo, Tania Díaz, et al.JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.JAMA Oncology|May 29, 2025
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung CancerArianna Marinello, Maria Rosa Ghigna, Julia K Rotow, et al.Pageof 53